臨床検査51巻4号

2007年04月発行

今月の主題 悪性リンパ腫 各論

悪性リンパ腫の治療戦略とそのEBM―ホジキン病

著者： 矢野尊啓¹

所属機関： ¹国立病院機構東京医療センター血液内科

ページ範囲：P.399 - P.407

　ホジキンリンパ腫では，臨床病期が最も重要な予後因子であり，限局期ではABVD療法2～4コースと局所放射線照射が行われ，90%以上の患者に長期生存が得られる．進行期ではABVD療法6～8コースが標準的治療とされるが，長期生存は70～80%にとどまり，予後不良と予測される例ではより強力な化学療法が検討されている．再発例，治療抵抗例では大量化学療法併用自己末梢血幹細胞移植の適応を考慮する．Rituximab，抗CD30抗体などの新たな薬剤も試みられつつある．〔臨床検査　51：399-407，2007〕

参考文献

１) Yung L, Linch D：Hodgkin's lymphoma. Lancet　361：943-951, 2003

２) Tucker MA, Coleman CN, Cox RS, et al：Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med　318：76-81, 1988

３) Bhatia S, Robison LL, Oberlin O, et al：Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med　334：745-751, 1996

４) Canellos GP, Anderson JR, Propert KJ, et al：Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD or MOPP alternating with ABVD. N Engl J Med　327：1478-1484, 1992

５) Hoppe RT：Radiation therapy in the management of Hodgkin's disease. Semin Oncol　17：704-715, 1990

６) Gospodarowicz MK, Meyer RM：The management of patients with limited-stage classical Hodgkin lymphoma. Hematology (Am Soc Hematol Educ Program)：53-258, 2006

７) Takenaka T, Mikuni C, Miura A, et al：Alternating combination chemotherapy C-MOPP (cyclophosphamide, vincristine, procarbazine, prednisone) and ABVd (adriamycin, bleomycin, vinblastine, dacarbazine) in clinical stage II-IV Hodgkin's disease：a multicenter phase II study (JCOG 8905). The Lymphoma Study Group of the Japan Clinical Oncology Group. Jpn J Clin Oncol　30：146-152, 2000

８) Hasenclever D, Diehl V, Armitage JO, et al：A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med　339：1506-1514, 1998

９) Diehl V, Franklin J, Pfreundschuh M, et al：the German Hodgkin's Lymphoma Study Group：Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med　348：2386-2395, 2003

10) Aleman BM, Raemaekers JM, Tirelli U, et al：European Organization for Research and Treatment of Cancer Lymphoma Group：involved field radiotherapy for advanced Hodgkin's lymphoma. N Engl J Med　348：2396-2405, 2003

11) Laskar S, Gupta T, Vimal S, et al：Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine and dacarbazine chemotherapy：is there a need? JCO　22：62-68, 2004

12) Federico M, Bellei M, Brice P, et al：EBMT/GISL/ANZLG/SFGM/GELA Intergroup HD01 Trial. High-dose therapy and autologous stem cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy. J Clin Oncol　21：2320-2325, 2003

13) Horning SJ, Chao NJ, Negrin RS, et al：High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease：analysis of the Stanford University results and prognostic indices. Blood　89：801-813, 1997

14) Yuen AR, Rosenberg SA, Hoppe RT, et al：Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. Blood　89：814-822, 1997

15) Linch DC, Winfield D, Goldstone AH, et al：Dose intensification with autologous bone marrow transplantation in relapsed and resistant Hodgkin's disease：results of a BLNI randomised trial. Lancet　341：1051-1054, 1993

16) Schmitz N, Pfistner B, Sextro M, et al：Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem cell transplantation for relapsed chemosensitive Hodgkin's disease：A randomised trial Lancet　359：2065-2071, 2002

17) Bartlett NL：Therapies for relapsed Hodgkin lymphoma：Transplant and non-transplant approaches including immunotherapy. Hematology (Am Soc Hematol Educ Program)：245-251, 2005　

18) Freytes CO, Loberiza FR, Rizzo JD, et al：Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma：a report of the International Bone Marrow Transplant Registry. Blood　104：3797-3803, 2004　

19) Schmitz N, Sureda A, Robinson S, et al：Allogeneic transplantation of hematopoietic stem cells after nonmyeloablative conditioning for Hodgkin's disease：indications and results. Semin Oncol　31：27-32, 2004

20) Nogová L, Rudiger T, Engert A：Biology, clinical course and management of nodular lymphocyte-predominant Hodgkin lymphoma. Hematology (Am Soc Hematol Educ Program)：266-272, 2006

21) Borchmann P, Schnell R, Fuss I, et al：Phase I trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma. Blood　100：3101-3107, 2002